8-K: Cardinal Health Elevates FY25 Earnings Outlook and Unveils Ambitious Long-Term Growth Strategy

Cardinal Health announced a significant increase in its fiscal year 2025 earnings guidance, provided robust preliminary fiscal year 2026 outlook, and detailed new long-term financial targets alongside strategic expansions in specialty solutions and distribution network enhancements.

Summary

• Cardinal Health is raising and narrowing its fiscal year 2025 non-GAAP diluted EPS guidance to $8.15 to $8.20, up from $8.05 to $8.15, representing a 9% growth at the mid-point.
• The company is establishing preliminary fiscal year 2026 non-GAAP diluted EPS guidance of $9.10 to $9.30, indicating a 13% growth at the mid-points.
• Cardinal Health is confirming its long-term target of 12% to 14% non-GAAP diluted EPS Compound Annual Growth Rate (CAGR) for fiscal years 2026 to 2028.
• The long-term target for Pharmaceutical and Specialty Solutions profit is being raised to 5% to 7% normalized growth.
• The long-term target for 'Other' profit is being raised to approximately 10% normalized growth.
• The Global Medical Products and Distribution (GMPD) long-term target is updated to $50 million+ of profit growth per year after fiscal year 2026.
• The company expects at least $10 billion in total adjusted free cash flow over the next three years (FY26 to FY28).
• Baseline share repurchase plans are being raised to at least $750 million per year, up from the previous annual baseline expectation of $500 million.
• Strategic updates include the launch of 'The Specialty Alliance' multi-specialty MSO platform, encompassing the recently acquired GI Alliance and the newly established Urology Alliance, supporting approximately 2,200 providers across 28 states and over 450 sites of care.
• Continued investments in Biopharma Solutions are planned, with PPS Analytics and SoNaR data platforms expanding into oncology, gastroenterology, and rheumatology, and the Sonexus Access and Patient Support hub platform expected to more than double its supported therapies by fiscal year 2028.
• The Consumer Health Logistics Center (CHLC) in Ohio has begun taking inventory and will be fully operational in July 2025, as the first step in increasing capacity and driving efficiencies in pharmaceutical distribution.
• Cardinal Health plans to build a new state-of-the-art forward distribution center with automation technology, currently evaluating multi-state locations.
• The new customer ordering platform, Vantus HQ, has reached critical mass, providing enhanced capabilities for retail customers.
• Nuclear and Precision Health Solutions plans to invest over $150 million over the next three years to support the theranostics and PET product pipeline, expanding its cyclotron network and Center for Theranostics Advancement.
• at-Home Solutions has begun realizing anticipated acquisition synergies from the Advanced Diabetes Supply (ADS) acquisition, with distribution network integration expected within six months, and plans for further automated distribution center expansion at three additional sites.
• OptiFreight Logistics is expanding its offerings within the hospital pharmacy setting.
• The Global Medical Products and Distribution business continues to execute its improvement plan, which has returned the business to positive profit and cash flow generation.

Sentiment

Score: 9

Explanation: The document presents a highly positive outlook with raised financial guidance for the current fiscal year, strong preliminary guidance for the next, and ambitious long-term growth targets. Strategic investments and expansions in high-growth areas like specialty solutions and theranostics, coupled with increased share repurchases and robust free cash flow generation, indicate strong confidence in future performance and value creation.

Positives

• Increased fiscal year 2025 non-GAAP diluted EPS guidance to $8.15-$8.20, up from $8.05-$8.15, indicating stronger near-term profitability.
• Provided robust preliminary fiscal year 2026 non-GAAP diluted EPS guidance of $9.10-$9.30, projecting 13% growth at the mid-points.
• Confirmed an ambitious long-term non-GAAP diluted EPS CAGR target of 12%-14% for FY26-FY28, signaling sustained growth expectations.
• Raised long-term profit growth targets for Pharmaceutical and Specialty Solutions (5%-7% normalized) and Other segments (~10% normalized), highlighting strength in higher-margin businesses.
• Anticipates generating at least $10 billion in total adjusted free cash flow over the next three years (FY26-FY28), demonstrating strong cash generation capabilities.
• Increased baseline share repurchase plans to at least $750 million per year, up from $500 million, indicating enhanced shareholder returns.
• Launched 'The Specialty Alliance' MSO platform, expanding into high-growth areas like urology and supporting a large network of providers (2,200 across 28 states, 450+ sites).
• Announced continued investments in Biopharma Solutions, including the expansion of PPS Analytics and SoNaR platforms and the expected doubling of Sonexus Access and Patient Support hub supported therapies by FY28.
• The Consumer Health Logistics Center (CHLC) in Ohio will be fully operational in July 2025, expected to increase capacity and drive efficiencies in pharmaceutical distribution.
• Plans to build a new state-of-the-art forward distribution center with advanced automation technology.
• Vantus HQ customer ordering platform has reached critical mass, enhancing capabilities for retail customers.
• Significant investment of over $150 million over three years in Nuclear and Precision Health Solutions to capitalize on the growing theranostics and PET product pipeline.
• Realizing anticipated acquisition synergies from the Advanced Diabetes Supply (ADS) acquisition, with integration progressing as planned.
• Opening of an automated Fort Worth facility and plans for further automated distribution center expansion for at-Home Solutions.
• OptiFreight Logistics is expanding its offerings within the hospital pharmacy setting, supporting business growth.
• The Global Medical Products and Distribution (GMPD) business has returned to positive profit and cash flow generation due to successful execution of its improvement plan.

Risks

• Failure to achieve strategic objectives, including the continued execution of the GMPD Improvement Plan initiatives, potentially due to tariffs, an uncertain global economic environment, Cardinal Health Brand sales, or ongoing inflationary pressures.
• Competitive pressures in Cardinal Health's various lines of business, including the risk that customers may reduce purchases, terminate, or not renew contracts, whether due to price increases or otherwise.
• Inability to manage uncertainties associated with the pricing of branded pharmaceuticals, including as a result of legislative or executive actions.
• Risks associated with litigation matters, including a Department of Justice investigation focused on potential violations of the Anti-Kickback Statute and False Claims Act.
• Events outside of the company's control, such as weather or geopolitical events, which may impact demand for products or cause supply shortages affecting cost and ability to fulfill customer demand.
• The performance of the generics program, including the amount or rate of generic deflation and the company's ability to offset it and maintain other financial and strategic benefits.
• Risks associated with recently completed and pending acquisitions, including those arising from entry into new lines of businesses.

Future Outlook

Cardinal Health is projecting robust future growth, with non-GAAP diluted EPS expected to grow 13% in fiscal year 2026 and maintain a 12-14% CAGR through fiscal year 2028. The company anticipates generating at least $10 billion in adjusted free cash flow over the next three years and plans to increase baseline share repurchases to at least $750 million annually. This growth is expected to be driven by strategic investments and expansions in high-growth areas such as specialty solutions, biopharma, and the modernization of its core pharmaceutical distribution network.

Management Comments

• Jason Hollar, Chief Executive Officer: "We are proud of the strong and resilient foundation we have built that enables us to deliver compelling future growth. We look forward to highlighting the significant opportunities in front of Cardinal Health as we continue to evolve to reach our full potential."
• Aaron Alt, Chief Financial Officer: "With the benefits of our robust cash flow generation, continued investments in the business and accelerating contributions from higher-margin businesses, we are positioning our business to deliver sustainable long-term growth and value creation."

Industry Context

Cardinal Health operates within the dynamic and highly regulated healthcare distribution and medical products industry. Its strategic focus on expanding into specialty solutions, such as urology and oncology through 'The Specialty Alliance' and Biopharma Solutions, aligns with the broader industry trend towards higher-margin, specialized healthcare services and advanced diagnostics/therapeutics. Investments in automation for its distribution network address the ongoing need for efficiency and cost optimization in the high-volume, core distribution business. The company's MSO platforms reflect the industry's shift towards supporting independent physician practices and integrated care models.

Legal Proceedings

• The company notes risks associated with litigation matters, including a Department of Justice investigation focused on potential violations of the Anti-Kickback Statute and False Claims Act.

Stakeholder Impact

• Shareholders: Positive impact due to raised EPS guidance, strong long-term growth targets, increased free cash flow generation, and higher share repurchase plans, indicating potential for increased shareholder returns and value creation.
• Employees: Potential for growth and expansion in various segments (e.g., Specialty Alliance, Biopharma Solutions, distribution centers) could lead to job creation, career development opportunities, and overall stability.
• Customers (Providers/Hospitals/Pharmacies): Enhanced capabilities through new platforms like Vantus HQ, expanded MSO platforms, and improved distribution network aim to provide better service, product access, and operational efficiencies.
• Suppliers/Manufacturer Partners: Continued investments in Biopharma Solutions and expanded data platforms support manufacturer partners, potentially strengthening collaborations.
• Creditors: Robust cash flow generation and a disciplined capital allocation framework suggest strong financial health and liquidity, which is generally favorable for creditors.

Next Steps

• The Consumer Health Logistics Center (CHLC) in Ohio is expected to be fully operational in July 2025.
• A multi-state evaluation is underway for potential locations of a new state-of-the-art forward distribution center.
• The Sonexus Access and Patient Support hub platform is expected to more than double its supported therapies by fiscal year 2028.
• Continued investment of over $150 million is planned over the next three years in Nuclear and Precision Health Solutions.
• Completion of the distribution network integration of the Advanced Diabetes Supply (ADS) business is expected within six months.
• Further automated distribution center expansion is planned at three additional sites for at-Home Solutions, including two new distribution centers in the West and Northeast.
• Continued execution of the Global Medical Products and Distribution (GMPD) Improvement Plan.

Key Dates

Recommendation

Keywords

Healthcare distribution, Pharmaceutical distribution, Specialty solutions, Medical products, Supply chain, Logistics, Biopharma, Theranostics, PET products, Home health, Corporate governance, Financial outlook, EPS guidance, Free cash flow, Share repurchase, MSO platform, Acquisitions, Automation, Investor Day